Clinical

Dataset Information

0

A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer


ABSTRACT: This was a Phase 1, open-label, single-center study of CS-1008, an immunoglobulin G subclass 1 (IgG1) humanized monoclonal antibody, in subjects with advanced colorectal carcinoma who had received ≥ 1 prior chemotherapy regimen for metastatic disease. Primary study objectives were to determine the influence of the CS-1008 dose on the biodistribution, pharmacokinetics (PK) and tumor uptake of radiolabeled CS-1008 following a single infusion and following continuous sequential doses of CS-1008. Secondary objectives were to evaluate changes in tumor metabolism, antitumor response, and changes in serum apoptosis biomarkers and tumor response markers following treatment with CS-1008.

DISEASE(S): Colorectal Neoplasms

PROVIDER: 2096559 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2015-09-14 | GSE70797 | GEO
2007-09-10 | GSE8939 | GEO
| 2089205 | ecrin-mdr-crc
| PRJNA777368 | ENA
2015-09-14 | E-GEOD-70797 | biostudies-arrayexpress
| PRJNA188498 | ENA
| 2077407 | ecrin-mdr-crc
| PRJNA66287 | ENA
| PRJNA698674 | ENA
2019-02-01 | GSE125963 | GEO